Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at "Make Whole" Prices Biotech Investing
Amgen Submits Supplemental New Drug Application for Otezla® for Adults with Mild-To-Moderate Plaque Psoriasis Biotech Investing
Second Phase 3 Induction Study Confirms Upadacitinib ) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients Biotech Investing
Torchlight Loans Metamaterial US$10,000,000, Allowing Metamaterial to Execute on Business Plan in Advance of Shareholder Votes Cleantech Investing
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion Biotech Investing
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart
